title: Pragmatic randomized clinical trials: a proposal to enhance evaluation of new cancer therapies with early signs of exceptional activity.
authors.affiliation: Pfizer Oncology, New York maria.koehler@pfizer.com.
authors.forename: M
authors.initials: M
authors.lastname: Koehler
authors.affiliation: Pfizer Oncology, Cambridge, USA.
authors.forename: E T
authors.initials: ET
authors.lastname: Donnelly
authors.affiliation: Pfizer Oncology, Regional Medical Affairs, Berlin, Germany.
authors.forename: D
authors.initials: D
authors.lastname: Kalanovic
authors.affiliation: Pfizer, Worldwide Safety and Regulatory, Groton, USA.
authors.forename: R
authors.initials: R
authors.lastname: Dagher
authors.affiliation: Pfizer Oncology, New York.
authors.forename: M L
authors.initials: ML
authors.lastname: Rothenberg
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004341:Drug Evaluation / Q000379:methods / Q000639:trends; D006801:Humans; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D018579:Patient Selection; D010879:Piperazines / Q000627:therapeutic use; D010880:Piperidines; D064792:Pragmatic Clinical Trials as Topic / Q000379:methods*; D011720:Pyrazoles / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D012107:Research Design / Q000639:trends
chemical_list: D000970:Antineoplastic Agents; D010879:Piperazines; D010880:Piperidines; D011720:Pyrazoles; D011725:Pyridines; D011743:Pyrimidines; C551803:ibrutinib; C500026:palbociclib; D000225:Adenine